Chamakh-Ayari R., Bras Goncalves Rachel, Bahi-Jaber N., Petitdidier Elodie, Markikou-Ouni W., Aoun K., Moreno J., Carrillo E., Salotra P., Kaushal H., Singh Negi N., Arevalo J., Falconi-Agapito F., Privat A., Cruz M., Pagniez Julie, Papierok G.M., Bel Haj Rhouma F., Torres P., Lemesre Jean-Loup, Chenik M., Meddeb-Garnaoui A. (2014). In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis. PLoS One, 9 (5), e92708 [12 p. en ligne]. ISSN 1932-6203.
Titre du document
In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis
Année de publication
2014
Auteurs
Chamakh-Ayari R., Bras Goncalves Rachel, Bahi-Jaber N., Petitdidier Elodie, Markikou-Ouni W., Aoun K., Moreno J., Carrillo E., Salotra P., Kaushal H., Singh Negi N., Arevalo J., Falconi-Agapito F., Privat A., Cruz M., Pagniez Julie, Papierok G.M., Bel Haj Rhouma F., Torres P., Lemesre Jean-Loup, Chenik M., Meddeb-Garnaoui A.
Source
PLoS One, 2014,
9 (5), e92708 [12 p. en ligne] ISSN 1932-6203
PSA (Promastigote Surface Antigen) belongs to a family of membrane-bound and secreted proteins present in several Leishmania (L.) species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice. We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S) produced in a L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm) or L. braziliensis (CCLb) or visceral leishmaniasis due to L. donovani (CVLd) and in healthy individuals. Healthy individuals were subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum infection) or non immune/naive individuals (HLR: Healthy Low Responders), depending on whether they produce high or low levels of IFN-gamma in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-gamma, granzyme B and IL-10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-alpha in more. No significant cytokine response was observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase in CD4+ T cells producing IFN-gamma after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the percentage of IFN-gamma-producing CD4+ T cells and the released IFN-gamma. We showed that the LaPSA-38S protein was able to induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection.
Plan de classement
Lutte [052PHLEIS03]
Descripteurs
LEISHMANIOSE ; VACCINATION ; ANTIGENE ; EVALUATION ; PROTEINE ; PHENOTYPE ; IMMUNITE ; ANTICORPS ; EXPERIMENTATION IN VITRO ; ANALYSE STATISTIQUE ; ETUDE EXPERIMENTALE ; ETUDE COMPARATIVE ; TECHNIQUE PCR ; CYTOMETRIE ; TEST ELISA
Description Géographique
INDE ; PEROU ; ESPAGNE ; FRANCE ; TUNISIE
Localisation
Fonds IRD [F B010062178]
Identifiant IRD
fdi:010062178
